BioNTech Aktie
WKN DE: A2PSR2 / ISIN: US09075V1026
|
23.09.2025 00:45:54
|
Why BioNTech Stock Bumped Higher Today
A victory on the regulatory front and a bullish analyst move were the twin news items propelling BioNTech's (NASDAQ: BNTX) shares higher as the stock trading week began on Monday. The Germany-based biotech's equity rose by almost 3% in value during the session, comparing well to the 0.4% improvement of the S&P 500 index. Friday afternoon, a vaccine advisory panel of the Centers for Disease Control and Prevention (CDC) narrowly voted against recommending a doctor's prescription to obtain shots of Covid vaccines in this country. BioNTech came to prominence during the Covid era as the co-developer (with Pfizer) of the go-to jab Comirnaty. To a degree, its reputation still rests on the product. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu BioNTech (ADRs)mehr Nachrichten
Analysen zu BioNTech (ADRs)mehr Analysen
| 22.08.25 | BioNTech Neutral | UBS AG | |
| 05.08.25 | BioNTech Buy | Deutsche Bank AG | |
| 05.08.25 | BioNTech Neutral | UBS AG | |
| 05.08.25 | BioNTech Buy | Jefferies & Company Inc. | |
| 13.06.25 | BioNTech Buy | Deutsche Bank AG |
Aktien in diesem Artikel
| BioNTech (ADRs) | 92,00 | -0,54% |
|
Letzte Top-Ranking Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.